Search - tctmd.com

Displaying 61 - 80 of 424

Sort: Relevancy | Date

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

News Conference News AHA 2022

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

Yael L. Maxwell

November 07, 2022

New Tool Assesses Risk in Acute HF Then Suggests Next Steps, Cutting Later Events

News Conference News AHA 2022

New Tool Assesses Risk in Acute HF Then Suggests Next Steps, Cutting Later Events

Yael L. Maxwell

November 07, 2022

PRECISE CT-Based Strategy Allows Clinicians to ‘Do Less’ for Stable Chest Pain

News Conference News AHA 2022

PRECISE CT-Based Strategy Allows Clinicians to ‘Do Less’ for Stable Chest Pain

Yael L. Maxwell

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Most Patient-Reported Outcome Measures in CVD Fall Short

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

September 23, 2022

To Cure What Ails US Healthcare: Creativity, Value, Fairness, Says FDA’s Califf

News Conference News TCT 2022

To Cure What Ails US Healthcare: Creativity, Value, Fairness, Says FDA’s Califf

September 18, 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

August 27, 2022

Stroke, Bleeding Risks Key for Assessing Potential LAAO Benefit

News Daily News

Stroke, Bleeding Risks Key for Assessing Potential LAAO Benefit

August 17, 2022

Few Adults Eligible for Primary Prevention With Statins in Latest ESC Guidelines

News Daily News

Few Adults Eligible for Primary Prevention With Statins in Latest ESC Guidelines

Michael O'Riordan

July 06, 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

May 23, 2022

Good News and Bad for High-Intensity Statin Use in ASCVD

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

News Daily News

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

May 03, 2022

The NCDR Has Made a Difference, but Experts See Room for Growth

News Daily News

The NCDR Has Made a Difference, but Experts See Room for Growth

April 28, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.